Drugs / Vermurafenib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02115035 | Jul 2014 → Jul 2017 | plasma cell myeloma | University of Arkansas | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vermurafenib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02115035 ↗ |
| Route | Oral | “twice daily orally” NCT02115035 ↗ |